Back to search
FDAFDA · Food and drugs·Recall number D-0314-2021

Tremfya (guselkumab) Injection, 100 mg/mL, one single-dose prefilled syringe per carton, Rx only, Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044; NDC 57894-640-01.

Published April 7, 2021 · Recall initiated: March 9, 2021

Summary

FDA records drug Class III recall D-0314-2021, published April 7, 2021 and initiated March 9, 2021. Recalling firm: Cardinal Health Inc.; Status: Terminated; Reported quantity: 48 boxes; Lot: KESOY.AI Exp. 04/2022. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Temperature Abuse

What to do

Voluntary: Firm initiated · Letter

Get an email if TREMFYA has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
TREMFYA
Manufacturer
Cardinal Health Inc.
Distributor
AL, LA, MS, TN
Lot
KESOY.AI Exp. 04/2022
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tremfya (guselkumab) Injection, 100 mg/mL, one single-dose prefilled syringe per carton, Rx only, Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044; NDC 57894-640-01. recalled?

Yes. FDA published recall D-0314-2021 on April 7, 2021. Reported hazard: Temperature Abuse

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: TREMFYA.